您好,欢迎您

2024 ESMO预告|乳腺癌研究口头报告摘要概览

07月19日
编译:肿瘤资讯
来源:2024 ESMO官网

2024年欧洲肿瘤内科学会(ESMO)年会即将于9月13-17日在西班牙巴塞罗那盛大开幕。作为肿瘤学界的盛会,本次会议广泛覆盖了从基础到临床的前沿研究,为医疗专业人士提供了一个交流最新发现和多学科讨论的学术平台。

ESMO官方网站已提前公布了除LBA(Late-Breaking Abstract)之外的摘要标题。本期【肿瘤资讯】整理了乳腺癌领域的重点研究摘要,包括简短口头报告(MO)和口头报告(O),以期为读者带来最前沿的学术资讯。

优选论文专场——转移性乳腺癌

Proffered Paper session - Breast cancer, metastatic

专场时间:2024年09月13日16:00 - 17:30(本文时间均为西班牙时间,比北京时间晚6个小时)

专场地点:Barcelona Auditorium - Hall 2

本专场有3个LBA摘要待确认(TBC)

摘要号:340O

Ⅱ期ICARUS-BREAST01研究:Patritumab Deruxtecan(HER3-DXd)在 HR+/HER2- 晚期乳腺癌患者中的疗效、安全性和生物标志物分析

Efficacy, safety and biomarker analysis of ICARUS-BREAST01: a phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC)

讲者:Barbara Pistilli (Villejuif, Cedex, France)

简短口头报告专场——早期乳腺癌

Mini oral session - Breast cancer, early stage

专场时间:2024年09月14日10:15-11:45

专场地点:Barcelona Auditorium - Hall 2

本专场有2个LBA摘要TBC

摘要号:233MO

HR 阳性、HER2 阳性乳腺癌的卵巢功能抑制:HERA 试验的探索性分析

Ovarian Function Suppression in HR-positive, HER2-positive Breast Cancer: An Exploratory Analysis from the HERA Trial

讲者:Sohyun Moon (Seoul, Korea, Republic of)

摘要号:234MO

解释年龄、内分泌治疗持续性与HR阳性早期乳腺癌复发风险之间的关系:一项全国性队列研究

Explaining the Relationships between Age, Endocrine Therapy Persistence and Risk of Recurrence in Hormone-Positive Early Breast Cancer: A Nationwide Cohort Study

讲者:Elise Dumas (Paris, France)

摘要号:235MO 

NATALEE研究:瑞波西利+非甾体芳香化酶抑制剂(NSAI)在HR+/HER2- 早期乳腺癌年轻患者中的疗效和安全性

Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE

讲者:Sherene Loi (Melbourne, Australia, VIC)

摘要号:236MO

Ⅰ期 TNBC 新辅助化疗后的病理学完全缓解和生存期:一项基于注册研究的分析结果

Pathologic complete response and survival after neoadjuvant chemotherapy in stage I TNBC: a registry-based study

讲者:Manon De Graaf (Amsterdam, Netherlands)

摘要号:237MO

在接受新辅助紫杉类药物为基础治疗未经免疫治疗的早期TNBC中,TNBC-DX基因组检测的应用

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy

讲者:Miguel Martin Jimenez (Madrid, Spain)

摘要号:238MO

PROMENADE:帕博利珠单抗在早期三阴性ER-low乳腺癌中的真实世界法国队列研究

PROMENADE: PembROlizuMab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohort

讲者:Francois Cherifi (Caen, Cedex 5, France)

摘要号:239MO

HER2+ 早期乳腺癌的 TILs 和总生存期:ShortHER 试验的 10 年更新分析

TILs and overall survival (OS) in HER2+ early breast cancer (eBC): 10-year (yr) updated analysis of the ShortHER trial

讲者:Maria Vittoria Dieci (Padova, Italy) 

简短口头报告专场1——转移性乳腺癌

Mini oral session1- Breast cancer, metastatic

专场时间:2024年09月15日08:00-10:00

专场地点:Barcelona Auditorium - Hall 2

本专场有2个LBA摘要TBC

摘要号:341MO

衰老对晚期乳腺癌遗传和转录景观的影响:AURORA Program(BIG 14-01)亚组分析

Impact of aging on the genetic and transcriptional landscape of advanced breast cancer: an AURORA Program (BIG 14-01) subanalysis

讲者:Gabriele Zoppoli (Genova, Italy, GE)

摘要号:342MO

628 例携带BRCA1、BRCA2 或 PALB2 致病变异的转移性HR阳性乳腺癌患者的结果:基因组学和靶向治疗测序的真实世界数据分析

Metastatic Hormone Receptor-Positive Breast Cancer Outcomes in 628 patients with BRCA1, BRCA2, or PALB2 pathogenic variants: Real World Data Analysis of Genomics and Targeted Therapy Sequencing

讲者:Gerneiva Parkinson (Stanford, United States of America)

摘要号:343MO

揭示德曲妥珠单抗(T-DXd)的作用机制和耐药性:DAISY 试验的补充生物标志物分析

Unraveling the mechanisms of action and resistance to Trastuzumab deruxtecan (T-DXd): supplementary biomarker analyses from DAISY trial

讲者:Maria Fernanda Mosele (Villejuif, France)

摘要号:344MO

ESG401,一种新型Trop2抗体偶联药物(ADC),及其在 HER2 阴性转移性乳腺癌伴脑转移中的疗效证据

ESG401, a novel Trop2 antibody-drug conjugate (ADC), and its efficacy evidence in HER2-negative metastatic breast cancer with brain metastases

讲者:马飞 (中国,北京)

摘要号:345MO

IBI354(抗 HER2 ADC)治疗晚期实体瘤和乳腺癌患者:Ⅰ期研究的结果

IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): results from a phase I study

讲者:Charlotte Lemech (Randwick, Australia)

摘要号:346MO

HER2 驱动的乳腺癌和其他恶性肿瘤中T-DXd相关间质性肺病(ILD)的情况:来自法国大型真实世界研究队列的分析结果

Trastuzumab Deruxctecan (T-DXd) associated interstitial lung disease (ILD) in a large real-world French cohort of patients with HER2-driven breast cancer and other malignancies

讲者:Anthony Canellas (Paris, Cedex 20, France)

简短口头报告专场2——转移性乳腺癌

Mini oral session2- Breast cancer, metastatic

专场时间:2024年09月16日08:30-10:00

专场地点:Barcelona Auditorium - Hall 2

本专场有1个LBA摘要 TBC

摘要号:347MO

Ivonescimab 联合化疗作为TNBC一线治疗的安全性和有效性

The safety and efficacy of ivonescimab in combination with chemotherapy as first-line (1L) treatment for triple-negative breast cancer (TNBC)

讲者:王晓稼(中国, 杭州)

摘要号:348MO

PM8002/BNT327 联合白蛋白结合型紫杉醇一线治疗局晚期或转移性TNBC的安全性和有效性:一项Ib/II期研究

A Phase Ib/II Study to Assess the Safety and Efficacy of PM8002/BNT327 in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer

讲者:吴炅(中国, 上海)

摘要号:349MO

ESG401(一种新型 Trop2靶向ADC)在不同亚型转移性乳腺癌患者中的 Ia/Ib 期研究结果

Results from a Phase Ia/Ib Study of ESG401, a Novel Trop2 Antibody-Drug Conjugate, in Patients with Different Subtypes of Metastatic Breast Cancer

讲者:马飞(中国, 北京)

摘要号:320MO

Tibremciclib(BPI-16350)联合氟维司群用于内分泌治疗后进展的 HR+/HER2- 晚期乳腺癌患者:一项随机、多中心、双盲、III 期研究

Tibremciclib (BPI-16350) plus fulvestrant in patients with HR+/HER2- advanced breast cancer after progressing on endocrine therapy: A randomized, multicenter, double-blind, phase III study

讲者:胡夕春(中国, 上海)

摘要号:350MO

在HR+/HER2+转移性乳腺癌中添加CDK4/6抑制剂瑞波西利而豁免化疗 - 随机III期DETECT V试验的第二次中期疗效分析

Omission of chemotherapy and addition of the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer–second interim efficacy analysis of the randomized Phase III DETECT V trial

讲者:Wolfgang Janni (Ulm, Germany)

优选论文专场——早期乳腺癌

Proffered Paper session - Breast cancer, early stage

专场时间:2024年09月16日10:15 - 11:45

专场地点:Barcelona Auditorium - Hall 2

本专场有3个LBA摘要TBC

摘要号:231O

局部区域低剂量与常规剂量放疗在早期乳腺癌中的比较:HypoG-01 Ⅲ期UNICANCER试验的5年结果

Locoregional hypo vs normofractionated RT in early breast cancer: 5 years results of the HypoG-01 phase 3 UNICANCER trial

讲者:Sofia Rivera (Villejuif, Cedex, France)

摘要号:232O

高强度运动干预对复发和生存的影响:OptiTrain乳腺癌试验

Effects of a high-intensity exercise intervention on recurrence and survival: the OptiTrain breast cancer trial

讲者:Helene Rundqvist (Stockholm, Sweden)

 


资料来源

https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session

责任编辑:肿瘤资讯-Jina
排版编辑:肿瘤资讯-张薪媛


推荐阅读

2024 ESMO|肺癌相关专场口头摘要信息速览

2024 ESMO丨消化道肿瘤重磅研究一文前瞻

2024 ESMO|硕果累累,36 项中国研究入选口头报告


               
版权声明
本文专供医学专业人士参考,未经著作人许可,不可出版发行。同时,欢迎个人转发分享,其他任何媒体、网站如需转载或引用本网版权所有内容,须获得授权,且在醒目位置处注明“转自:良医汇-肿瘤医生APP”。